Keywords: Lemtrada, Alemtuzumab, Sanofi-Aventis, Genzyme, Multiple sclerosis, Phase II
Positive Ph II five-year alemtuzumab data presented by Genzyme
Article | 18 April 2011
Genzyme, which is now a wholly-owned subsidiary of French drug major Sanofi-Aventis Group (Euronext: SAN) reported additional five-year patient data ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
